• Consensus Rating: Buy
  • Consensus Price Target: $3.25
  • Forecasted Upside: 615.86%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.45
▲ +0.01 (2.25%)

This chart shows the closing price for IGC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IGC Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IGC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IGC

Analyst Price Target is $3.25
▲ +615.86% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for IGC Pharma in the last 3 months. The average price target is $3.25, with a high forecast of $3.25 and a low forecast of $3.25. The average price target represents a 615.86% upside from the last price of $0.45.

This chart shows the closing price for IGC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in IGC Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/21/2024Ascendiant Capital MarketsReiterated RatingBuy ➝ Buy$3.25 ➝ $3.25
(Data available from 7/16/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/17/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/17/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/17/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
IGC Pharma logo
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Read More

Today's Range

Now: $0.45
Low: $0.45
High: $0.46

50 Day Range

MA: N/A

52 Week Range

Now: $0.45
Low: $0.25
High: $0.91

Volume

124,819 shs

Average Volume

154,627 shs

Market Capitalization

$34.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of IGC Pharma?

The following sell-side analysts have issued research reports on IGC Pharma in the last twelve months: Ascendiant Capital Markets, and StockNews.com.
View the latest analyst ratings for IGC.

What is the current price target for IGC Pharma?

1 Wall Street analysts have set twelve-month price targets for IGC Pharma in the last year. Their average twelve-month price target is $3.25, suggesting a possible upside of 615.9%. Ascendiant Capital Markets has the highest price target set, predicting IGC will reach $3.25 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $3.25 for IGC Pharma in the next year.
View the latest price targets for IGC.

What is the current consensus analyst rating for IGC Pharma?

IGC Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IGC will outperform the market and that investors should add to their positions of IGC Pharma.
View the latest ratings for IGC.

What other companies compete with IGC Pharma?

How do I contact IGC Pharma's investor relations team?

IGC Pharma's physical mailing address is 4336 Montgomery Ave, BETHESDA, MD 20814-4443, United States. The construction company's listed phone number is (301) 983-0998 and its investor relations email address is [email protected]. The official website for IGC Pharma is www.igcinc.us. Learn More about contacing IGC Pharma investor relations.